RESUMEN
An HIV-infected patient was diagnosed with acute hepatitis E infection in our hospital. An epidemiological inquiry was performed to collect demographic, food and animal exposure variables in order to identify the potential route of transmission. The patient reported that his family traditionally hunted wild boar for food. All family members were analysed for hepatitis E virus infection. Additionally, route of transmission by wild boar meat consumption and prevalence of HEV infection among wild boar from the same hunting area were investigated. In all-family members (n = 8), HEV-RNA was amplified. Two wild boar meat slices consumed was analysed, showing the presence of HEV. The virus isolated was consistent with genotype 3, revealing 100% homology between family members and meat. Additionally, we tested nine wild boar hunted in the same hunting area. All of them were RNA-HEV positive, isolating the same HEV genotype 3 viral strain. We demonstrated by phylogenetic analysis zoonotic transmission of HEV by wild boar meat consumption. The prevalence of HEV infection among wild boar found in our study suggests that this species is an important route of transmission to human.
Asunto(s)
Brotes de Enfermedades , Microbiología de Alimentos , Hepatitis E , Carne de Cerdo , Animales , Genotipo , Hepatitis E/etiología , Hepatitis E/transmisión , Hepatitis E/virología , Virus de la Hepatitis E/genética , Virus de la Hepatitis E/aislamiento & purificación , Infecciones por VIH/complicaciones , Filogenia , ARN Viral/aislamiento & purificación , España , Sus scrofa , Zoonosis/transmisión , Zoonosis/virología , Humanos , Carne de Cerdo/virologíaRESUMEN
Our aim was to analyze the influence of HLA-B haplotypes on liver fibrosis progression in HIV/hepatitis C virus (HCV) co-infected patients. Retrospective longitudinal study including HIV/HCV, non-cirrhotic and HCV treatment-naïve patients. The main outcome variable was liver fibrosis progression of at least one stage. One hundred and four patients constituted the study population (F0-F1: 62 (59.6%); F2: 22 (21.2%); F3: 20 (19.2%)). During a median follow-up of 54.5 months (IQR: 26.2-77), 45 patients (43.3%) showed an increase in the stage of liver fibrosis (time to event: 29 (IQR: 14-49.5) months). HLA-B18pos patients more frequently had a higher and faster fibrosis progression rate (73.3%; 24 (IQR: 8-29) months) than HLA-B18neg patients (38.2%; 34.5 (IQR: 14.7-51.2) months). This association was also observed in the development of F3-F4 fibrosis among F0-F2 patients (HLA-B18pos: 69.2%; 18 (6.5-37) months vs HLA-B18neg: 28.2%; 37 (IQR: 19-52) months). These results could impact the timing of HCV therapy in F0-F2 patients.
Asunto(s)
Infecciones por VIH/tratamiento farmacológico , Antígeno HLA-B18/genética , Hepatitis C/tratamiento farmacológico , Cirrosis Hepática/inmunología , Adulto , Coinfección , Progresión de la Enfermedad , Femenino , Genotipo , Infecciones por VIH/complicaciones , Infecciones por VIH/genética , Infecciones por VIH/virología , Hepatitis C/complicaciones , Hepatitis C/genética , Hepatitis C/virología , Humanos , Cirrosis Hepática/etiología , Cirrosis Hepática/genética , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Índice de Severidad de la Enfermedad , Análisis de Supervivencia , Factores de Tiempo , Insuficiencia del Tratamiento , Carga ViralAsunto(s)
Infecciones por VIH/tratamiento farmacológico , Antígeno HLA-B18/genética , Hepatitis C/tratamiento farmacológico , Cirrosis Hepática/genética , Coinfección , Progresión de la Enfermedad , Genotipo , Infecciones por VIH/complicaciones , Infecciones por VIH/genética , Hepatitis C/complicaciones , Hepatitis C/genética , Humanos , Cirrosis Hepática/etiología , Cirrosis Hepática/inmunología , Factores de Riesgo , Análisis de Supervivencia , Insuficiencia del TratamientoRESUMEN
Our aim was to evaluate the killer cell immunoglobulin-like receptors (KIRs) as a marker for the development of thrombocytopenia secondary to Peg-interferon (IFN) therapy in a cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infected patients. Patients were naive to HCV treatment, receiving a first course of Peg-IFN/Ribavirin combination therapy. Total platelet count (cells ml-1) was determined at each visit, determining platelet decline from baseline to weeks 1, 2, 4, 8 and 12 after starting therapy. The end point of the study was development of thrombocytopenia, defined as a platelet count of <1 50 000 cells ml-1. Fifty-eight HIV/HCV co-infected patients were included in the study, of whom 20 (34.4%) developed thrombocytopenia. The absence of KIR2DS2 was associated with higher and faster rate of thrombocytopenia (54.2% vs 22.5%; P=0.012; 6.6 vs 10.3 weeks; P=0.008). The absence of KIR2DS2 was associated with a greater decline in platelet count and development of thrombocytopenia during Peg-IFN treatment in HIV/HCV co-infected patients.